- |||||||||| Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - Mar 12, 2021 P1, N=54, Recruiting, Not yet recruiting --> Recruiting Trial primary completion date: Sep 2021 --> Sep 2023
- |||||||||| Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open, Trial primary completion date: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - Feb 9, 2021 P1, N=54, Recruiting, Trial primary completion date: Feb 2021 --> Mar 2020 Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2023 --> Sep 2021
- |||||||||| Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial primary completion date: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - Oct 12, 2020 P1, N=54, Not yet recruiting, Its affordable cost fulfils an unmet need of ITP patients, requiring the best second line of treatment in LMIC Trial completion date: Sep 2020 --> Jul 2023 | Trial primary completion date: Sep 2020 --> Jul 2023
- |||||||||| Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - Jul 13, 2020 P1, N=54, Recruiting, Trial primary completion date: Sep 2020 --> Feb 2021 Suspended --> Recruiting
- |||||||||| Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date, IO biomarker: ECOG-ACRIN E1912: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Apr 21, 2020 P3, N=519, Active, not recruiting, Not yet recruiting --> Recruiting Trial primary completion date: Mar 2021 --> Jun 2026
- |||||||||| Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date, IO biomarker: ECOG-ACRIN E1912: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Apr 9, 2020 P3, N=519, Active, not recruiting, Trial primary completion date: Mar 2021 --> Jun 2026 Trial primary completion date: Mar 2020 --> Mar 2021
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: NCI-2017-01957: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Apr 9, 2020 P1, N=30, Recruiting, Trial primary completion date: Mar 2020 --> Mar 2021 Trial completion date: Mar 2020 --> Jun 2021 | Trial primary completion date: Mar 2020 --> Jun 2021
- |||||||||| Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Trial suspension: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - Apr 2, 2020 P1, N=54, Suspended, Trial completion date: Mar 2020 --> Jun 2021 | Trial primary completion date: Mar 2020 --> Jun 2021 Recruiting --> Suspended
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Tecentriq (atezolizumab) / Roche
Trial suspension, Combination therapy, PD(L)-1 Biomarker: NCI-2017-01957: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Oct 23, 2018 P1, N=30, Suspended, Recruiting --> Suspended Recruiting --> Suspended
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Tecentriq (atezolizumab) / Roche
Enrollment open, Combination therapy, PD(L)-1 Biomarker: NCI-2017-01957: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - May 31, 2018 P1, N=30, Recruiting, N=360 --> 509 Suspended --> Recruiting
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Tecentriq (atezolizumab) / Roche
Trial suspension, Combination therapy, PD(L)-1 Biomarker, IO biomarker: NCI-2017-01957: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Apr 10, 2018 P1, N=30, Suspended, Trial primary completion date: May 2018 --> Feb 2019 Not yet recruiting --> Suspended
- |||||||||| alisertib (MLN8237) / Puma, Rituxan (rituximab) / Roche
Enrollment closed, Trial primary completion date, Combination therapy: Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma (clinicaltrials.gov) - Feb 19, 2018 P1, N=24, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Mar 2019
- |||||||||| Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open, Trial primary completion date: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - Nov 17, 2017 P1, N=54, Recruiting, Trial primary completion date: Jun 2018 --> Jun 2021 Not yet recruiting --> Recruiting | Trial primary completion date: May 2019 --> Sep 2020
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Tecentriq (atezolizumab) / Roche
New P1 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker: NCI-2017-01957: Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Oct 26, 2017 P1, N=30, Not yet recruiting,
- |||||||||| Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P1 trial: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - Jul 18, 2017 P1, N=54, Not yet recruiting,
- |||||||||| Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed, Combination therapy, Surgery, Metastases: Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - May 16, 2017 P1, N=12, Active, not recruiting, Not yet recruiting --> Recruiting | Trial primary completion date: May 2019 --> Sep 2020 Suspended --> Active, not recruiting
- |||||||||| Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
IO biomarker: ECOG-ACRIN E1912: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Apr 18, 2017 P3, N=519, Active, not recruiting, Suspended --> Active, not recruiting Trial primary completion date: Apr 2017 --> Mar 2020
- |||||||||| Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment change, Trial suspension, Combination therapy, Surgery, Metastases: Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 30, 2017 P1, N=11, Suspended, Trial primary completion date: Apr 2017 --> Mar 2020 N=28 --> 11 | Recruiting --> Suspended
|